Inspired by Nature.
Empowered by Technology.
Committed to Life.
Advancing Human-Relevant Systems to Reduce Reliance on Animal Models
Integrated • Predictive • Translational
Accelerating Smarter, More Human-Relevant Medicine
News & Press
NAMina Bio is building a translational ecosystem dedicated to advancing human-relevant models, New Approach Methodologies, and decision-ready platforms for biomedical innovation.
This page brings together NAMina Bio’s latest news, media mentions, scientific milestones, partnership updates, events, and thought leadership as we continue to connect advanced in vitro technologies, translational biology, and strategic collaboration across the life sciences ecosystem.
Excited to share that NAMina Bio is entering a new activation phase.
Our goal is to build a capital-efficient translational architecture platform that integrates human-relevant models, 3D bioprinting, organoids, organ-on-chip systems, multi-omics, and AI-driven analytics into decision-ready workflows for drug development.
The next step is focused on BioLabs-based launch planning, modular 3D bioprinting and advanced in vitro modeling capabilities, and partner-enabled execution across translational model systems.What makes this phase important is not only the technology itself, but the operating model: a lean integration layer that can design, orchestrate, and connect specialized platforms into structured programs for biotech and pharma.
NAMina Bio is now opening strategic conversations with aligned investors, technology partners, and translational research collaborators who share the vision of building more predictive, human-relevant drug development infrastructure.
From biology, to data, to better decisions.
New York, 5/10/2026
